Key result
Having basic health insurance was significantly associated with higher odds of receiving antiplatelet therapy among Chinese patients with ischaemic stroke or TIA (OR 1.47; 95% CI 1.09-1.99).
Why the study?
What are the rates and predictors of antithrombotic therapy use for secondary stroke prevention in China?
Cross-Sectional (n=2,283)
Yes
What are the rates and predictors of antithrombotic therapy use for secondary stroke prevention in China?
Odds Ratio: 1.47 (95% CI 1.09–1.99)
Adherence to guidelines for antithrombotic management in secondary stroke prevention in China is poor, heavily influenced by socioeconomic factors like insurance and income.
No takes yet. Share an insight, caveat, or question.
Insurance status associated with antiplatelet use in Chinese stroke/TIA patients; leaves open whether coverage expansion improves secondary prevention adherence.
Wang et al. (2010) conducted a cross-sectional in ischaemic stroke or transient ischaemic attack (n=2,283). Basic health insurance was evaluated on prescription for antiplatelet therapy (OR 1.47, 95% CI 1.09-1.99). Having basic health insurance was significantly associated with higher odds of receiving antiplatelet therapy among Chinese patients with ischaemic stroke or TIA (OR 1.47; 95% CI 1.09-1.99).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: